此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy

2026年6月29日 更新者:KeshuZhou、Henan Cancer Hospital

A Prospective Phase 2 Study of Lisaftoclax Plus Pirtobrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma After Failure of BTK-Targeted Therapy

This prospective, open-label, phase 2 study will evaluate the efficacy and safety of lisaftoclax in combination with pirtobrutinib in adults with relapsed or refractory mantle cell lymphoma following failure of prior BTK-targeted therapy.

The study includes two cohorts. Cohort 1 will enroll participants who experienced stable disease, disease progression, or intolerance following treatment with a covalent BTK inhibitor. Cohort 2 is an exploratory cohort enrolling participants who experienced stable disease, disease progression, or intolerance following treatment with a non-covalent BTK inhibitor other than pirtobrutinib or a BTK degrader.

Participants will receive oral pirtobrutinib 200 mg once daily in combination with oral lisaftoclax. Lisaftoclax will be administered using a dose ramp-up schedule, followed by a target dose of 600 mg once daily. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent.

研究概览

研究类型

介入性

注册 (估计的)

45

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Henan
      • Zhengzhou、Henan、中国
        • Henan Cancer Hospital
        • 首席研究员:
          • Keshu Zhou
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Participants must meet all of the following criteria:

    1. Age 18 years or older.
    2. Histologically and immunophenotypically confirmed mantle cell lymphoma.
    3. At least one measurable lesion.
    4. Received at least one prior systemic treatment regimen that included a BTK-targeted therapy, including a covalent BTK inhibitor, non-covalent BTK inhibitor, or BTK degrader, and had stable disease, disease progression, or intolerance during or after the most recent BTK-targeted therapy.
    5. Eastern Cooperative Oncology Group performance status of 0 to 2.
    6. Adequate hepatic, renal, and bone marrow function, defined as all of the following:

      * Aspartate aminotransferase and alanine aminotransferase ≤3 × upper limit of normal;

      • Total bilirubin ≤1.5 × upper limit of normal;
      • Creatinine clearance ≥30 mL/min;
      • Absolute neutrophil count ≥0.5 × 10^9/L;
      • Platelet count ≥30 × 10^9/L. Supportive treatment is permitted.
    7. Participants of reproductive potential must agree to use effective contraception during study treatment and for 3 months after the last dose of study treatment.
    8. Willing and able to comply with study procedures and follow-up assessments.
    9. Able to understand and voluntarily sign the informed consent form before screening.

Exclusion Criteria:

  • 1. Known hypersensitivity to pirtobrutinib, lisaftoclax, or any component or excipient of either study drug.

    2. Concurrent participation in another clinical study. 3. Prior treatment with any BCL-2 inhibitor. 4. Active central nervous system involvement, including parenchymal or leptomeningeal disease.

    5. Clinically significant uncontrolled cardiac or cardiovascular disease, or a history of myocardial infarction within 6 months before the planned initiation of pirtobrutinib.

    6. Uncontrolled active severe systemic bacterial, viral, fungal, or parasitic infection.

    7. Current treatment with strong CYP3A4 inhibitors or inducers and/or strong P-glycoprotein inhibitors.

    8. Positive human immunodeficiency virus test. 9. Active hepatitis B or hepatitis C infection, except:

    • Participants with detectable hepatitis B virus DNA whose disease is controlled may be enrolled at the investigator's discretion, provided that concurrent antiviral therapy is administered;
    • Participants with a history of hepatitis C virus infection who have completed antiviral treatment and have a viral load below the lower limit of quantification may be enrolled.

      10. Pregnant or breastfeeding women. 11. Unable to complete protocol-required study visits or procedures, including follow-up visits, or unable to comply with study requirements.

      12. Any other clinically significant current or prior medical condition that, in the investigator's judgment, may pose a risk to participant safety or interfere with study assessments, procedures, or completion.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort 1: Prior Covalent BTK Inhibitor Therapy
Participants with relapsed or refractory mantle cell lymphoma who experienced stable disease, disease progression, or intolerance following prior treatment with at least one covalent BTK inhibitor will receive lisaftoclax in combination with pirtobrutinib.
Lisaftoclax will be administered orally once daily. During Cycle 1, participants will undergo dose ramp-up with 20 mg on Day 1, 50 mg on Day 2, 100 mg on Day 3, 200 mg on Day 4, and 400 mg on Day 5. The target dose of 600 mg once daily will begin on Day 6 and continue thereafter. Each treatment cycle is 28 days. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or another protocol-defined reason for discontinuation.
Pirtobrutinib will be administered orally at a dose of 200 mg once daily beginning on Day 1 of Cycle 1. Each treatment cycle is 28 days. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or another protocol-defined reason for discontinuation.
实验性的:Cohort 2: Prior Non-Covalent BTK Inhibitor or BTK Degrader Therapy
Participants with relapsed or refractory mantle cell lymphoma who experienced stable disease, disease progression, or intolerance following prior treatment with a non-covalent BTK inhibitor other than pirtobrutinib or a BTK degrader will receive lisaftoclax in combination with pirtobrutinib.
Lisaftoclax will be administered orally once daily. During Cycle 1, participants will undergo dose ramp-up with 20 mg on Day 1, 50 mg on Day 2, 100 mg on Day 3, 200 mg on Day 4, and 400 mg on Day 5. The target dose of 600 mg once daily will begin on Day 6 and continue thereafter. Each treatment cycle is 28 days. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or another protocol-defined reason for discontinuation.
Pirtobrutinib will be administered orally at a dose of 200 mg once daily beginning on Day 1 of Cycle 1. Each treatment cycle is 28 days. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or another protocol-defined reason for discontinuation.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Complete Response Rate at 6 Months in Cohort 1
大体时间:At 6 months after initiation of study treatment
The proportion of participants in Cohort 1 who achieve a complete response at 6 months after initiation of study treatment, as assessed by the investigator according to the Lugano 2014 response criteria.
At 6 months after initiation of study treatment
Overall Response Rate in Cohort 2
大体时间:From the first dose of study treatment until disease progression, assessed up to 36 months
The proportion of participants in Cohort 2 who achieve a best overall response of complete response or partial response, as assessed by the investigator according to the Lugano 2014 response criteria.
From the first dose of study treatment until disease progression, assessed up to 36 months

次要结果测量

结果测量
大体时间
Duration of Response
大体时间:From the first documented response until disease progression or death, whichever came first, assessed up to 36 months
From the first documented response until disease progression or death, whichever came first, assessed up to 36 months
Progression-Free Survival
大体时间:From the first dose of study treatment until disease progression or death, whichever came first, assessed up to 36 months
From the first dose of study treatment until disease progression or death, whichever came first, assessed up to 36 months
Overall Survival
大体时间:From the first dose of study treatment until death from any cause, assessed up to 36 months
From the first dose of study treatment until death from any cause, assessed up to 36 months
Minimal Residual Disease Negativity Rate
大体时间:At baseline, assessed up to 4 weeks. Interim response assessment, from the first dose of study treatment till 3 cycles. End of induction treatment, from the first dose of study treatment till 3 cycles. Following period, every 6 months during follow-up.
At baseline, assessed up to 4 weeks. Interim response assessment, from the first dose of study treatment till 3 cycles. End of induction treatment, from the first dose of study treatment till 3 cycles. Following period, every 6 months during follow-up.
Number of Participants With Treatment-Emergent Adverse Events
大体时间:From the first dose of study treatment through 30 days after the last dose
From the first dose of study treatment through 30 days after the last dose

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年6月30日

初级完成 (估计的)

2028年10月30日

研究完成 (估计的)

2029年4月30日

研究注册日期

首次提交

2026年6月17日

首先提交符合 QC 标准的

2026年6月29日

首次发布 (实际的)

2026年7月6日

研究记录更新

最后更新发布 (实际的)

2026年7月6日

上次提交的符合 QC 标准的更新

2026年6月29日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅